DASATINIB
dasatinib 100 mg tablet, 30
DASATINIB (12842X)
12842X
Manner of administration:Oral
Restriction 17833
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Continuing treatment - third-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $421.56 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||